Genetic aberrations (eg, fusions/translocations, mutations, and amplifications) involving fibroblast growth factor receptors (FGFRs) are thought to drive disease in more than 100,000 new diagnoses each year in the United States.1,2
FGFR genetic aberrations (GAs) are present in 25% of cholangiocarcinomas.3 The most common FGFR GA is FGFR2 fusion, occurring in about 10%-16% of intrahepatic cholangiocarcinoma tumors.4 FGFR3 GAs are present in up to 20% of advanced urothelial carcinomas5 and cause more than 99% of achondroplasia cases.6
Our research supports the development of infigratinib,* an innovative investigational therapy that targets FGFR1-3 genetic alterations.7
- The safety and efficacy of infigratinib have not been established. There is no guarantee that infigratinib will receive health authority approval or become commercially available in any country for the uses being investigated.